Molecular Diagnostics Market is experiencing steady expansion, driven by the global shift toward rapid, decentralized, and ...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) is moving into a pivotal phase, with its flagship FebriDx test gaining ...
U.S. Molecular Diagnostics Market size was valued at USD 5.0 Billion in 2025 and is projected to reach USD 8.07 Billion by 2035 due to increasing chronic diseases in the country.Austin, April 03, 2026 ...
Diabetic screening capabilities are advancing as artificial intelligence cameras that detect diabetes are rolling out to ...
Biosensor reads creatinine in seconds, enabling rapid kidney function testing with high sensitivity for faster, point-of-care ...
A non-cash impairment charge of approximately $18.9 million related to in-process R&D intangible assets significantly ...
The allocated site is intended to support, subject to further development activities and approvals, the development of a state-of-the-art manufacturing facility dedicated to molecular diagnostic ...
FDA approval was granted to Lumos on Friday, prompting Atomo to launch the cash call via an institutional placement.
Stockhead on MSN
Atomo Diagnostics raising $4m to scale-up Pascal cassette supply amidst expected demand growth
The placement is priced at a discount of about 10% to the 15-day volume weighted average price.x ... Read More The post Atomo Diagnostics raising $4m to scale-up Pascal cassette supply amidst expected ...
Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures Progressing Clinical Pipeline and Regulatory Pathways for PCR Platform Strengthening ...
Waiting for chest X-rays or lab results to diagnose pneumonia and other lung-related diseases may not be necessary in the ...
Discusses CLIA Waiver Clearance for FebriDx, Capital Raise, and Commercialization Strategy March 30, 2026 6:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results